Open original FDA record ↗Recall record
- FDA identifier
- Z-0772-2024
- Company in FDA record
- Ortho-Clinical Diagnostics, Inc.
- FDA classification date
- Jan 19, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Affected lots may experience increased calibration failures or an increase in falsely elevated results.
Source facts
- Action
- On 27 November 2023, consignees who had been shipped the affected VITROS Anti-HBs Reagent Pack and Calibrator were notified of the issue via Urgent Production Correction Notification letters. Customers were instructed to immediately discontinue using, render unusable, and discard all affected lots of the affected product from their inventory. - QuidelOrtho will provide credit or replacement for the discarded product. - QuidelOrtho recommends a review of previous results between 12-30 mIU/mL, which were generated using an affected lot of VITROS anti-HBs Reagent Pack, where only anti-HBs testing was performed and was positive (for example, postvaccination testing) or where only anti-HBs was positive in the triple-panel test. If you have further questions, please contact QuidelOrtho's Global Services Organization (formerly Ortho Care) at 1-800-421-3311.
- Initiated
- 2023-11-27
- Root cause
- Nonconforming Material/Component
- Distribution
- Domestic distribution nationwide. OUS distribution to Bermuda, Australia, Brazil, Canada, Chile, China, Columbia, India, Japan, Mexico, Singapore, UK, France, Germany, Italy, Spain, Portugal, Russia, Denmark, Norway, Sweden, France, Belgium, and The Netherlands.
- Recall number
- Z-0772-2024
- Recall status
- Open, Classified
- CDRH record ID
- 204993
- FDA classified
- 2024-01-19
- Recall event number
- 93632